Media coverage about AstraZeneca (LON:AZN) has been trending somewhat positive on Saturday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by monitoring more than 6,000 blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AstraZeneca earned a coverage optimism score of 0.80 on their scale. InfoTrie also gave media stories about the biopharmaceutical company an news buzz score of 3 out of 10, indicating that recent media coverage is unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the headlines that may have effected AstraZeneca’s score:
- AstraZeneca (AZN) PT Set at GBX 6,350 by Credit Suisse Group (americanbankingnews.com)
- JPMorgan Chase & Co. Reaffirms Buy Rating for AstraZeneca (AZN) (americanbankingnews.com)
- What can we imagine from: – AstraZeneca PLC, (NYSE: AZN) (nysenewstoday.com)
- Market Risers: Imperial Brands PLC, AstraZeneca plc, National Grid plc & UNILEVER/PAR VTG FPD 0.031111 (directorstalkinterviews.com)
- AstraZeneca Group plc 2018 Q3 – Results – Earnings Call Slides (seekingalpha.com)
A number of analysts recently commented on AZN shares. Credit Suisse Group set a GBX 5,900 ($77.09) target price on AstraZeneca and gave the company a “buy” rating in a research report on Friday, July 27th. Barclays set a GBX 6,500 ($84.93) target price on AstraZeneca and gave the company a “buy” rating in a research report on Friday, July 27th. Deutsche Bank reaffirmed a “buy” rating and issued a GBX 6,000 ($78.40) target price on shares of AstraZeneca in a research report on Friday, July 27th. JPMorgan Chase & Co. set a GBX 5,800 ($75.79) target price on AstraZeneca and gave the company a “buy” rating in a research report on Friday, July 20th. Finally, Jefferies Financial Group boosted their target price on AstraZeneca from GBX 6,000 ($78.40) to GBX 6,050 ($79.05) and gave the company a “buy” rating in a research report on Friday, July 13th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. AstraZeneca presently has a consensus rating of “Hold” and a consensus target price of GBX 5,831.89 ($76.20).
AZN stock traded up GBX 79 ($1.03) during mid-day trading on Friday, reaching GBX 6,172 ($80.65). 2,861,442 shares of the company traded hands, compared to its average volume of 2,310,000. AstraZeneca has a fifty-two week low of GBX 4,260 ($55.66) and a fifty-two week high of GBX 5,520 ($72.13).
WARNING: “AstraZeneca (AZN) Getting Somewhat Favorable News Coverage, Report Finds” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/11/10/astrazeneca-azn-getting-somewhat-favorable-news-coverage-report-finds.html.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: What is the float in trading stocks?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.